NOVEMBER 2022LIFE SCIENCES REVIEW5Aaron Goodstein, Senior Director, Medical Safety Operations, Medical Devices & Global External Innovation and Michael Jacene, former Senior Director, Head of Compliance Strategy and Analytics for the Medical Device Sector, Johnson & JohnsonThe Importance of Independent Safety Input into the Medical Devices R&D ProcessCXO INSIGHTSLAST WORD212826Patrik Florencio, SVP and Chief Compliance & Risk Officer, Amicus Therapeutics and Michael Schneider, Executive Director, Global ERM and Compliance Auditing, Amicus TherapeuticsCarlos Pedraza, Ph.D., Director of CNS Biology, AlkermesCarlos Pedraza, PhD. Director of CNS Biology, AlkermesHow Technology Enhancesthe Effectiveness of Compliance ProgramsFrom Ideation To Portfolio Program: Innovation Vs Validation Inearly Drug DiscoveryFrom ideation to portfolio program: Innovation vs validation in early drug discoveryIN MY OPINION8Analytics as a competitive advantage takes 3 things ­ access, cleanliness and actionMatt Southwick, Executive Director Clinical Systems and Analytical Reporting,Amgen30
< Page 4 | Page 6 >